Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mason W Freeman

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 2, 2006
Statins, cholesterol, and the prevention of coronary heart diseaseMason W Freeman
Arteriosclerosis, Thrombosis, and Vascular Biology|May 27, 2006
Scavenger receptors in atherosclerosis: beyond lipid uptakeKathryn J Moore, Mason W Freeman
Drug Discovery Today. Therapeutic Strategies|May 12, 2009
Targeting Innate Immunity for CV BenefitKathryn J Moore, Mason W Freeman
Nature Medicine|February 4, 2003
eLiXiRs for restraining inflammationMason W Freeman, Kathryn J Moore
The New England Journal of Medicine|October 24, 2019
Case 22-2019: A 65-Year-Old Woman with Myopathy. ReplyMason W Freeman, Amanda C Guidon, Sheila L Arvikar
Biochemical and Biophysical Research Communications|October 3, 2003
Activation of signaling pathways by putative scavenger receptor class A (SR-A) ligands requires CD14 but not SR-AWoojin Scott Kim, Christine M Ordija, Mason W Freeman
Journal of Molecular Medicine (Berlin, Germany)|May 22, 2002
Nuclear hormone receptors and cholesterol trafficking: the orphans find a new homeMichael L Fitzgerald, Kathryn J Moore, Mason W Freeman
The New England Journal of Medicine|May 10, 2023
Baxdrostat for Treatment-Resistant Hypertension. ReplyMason W Freeman, Yuan-Di Halvorsen, Morris J Brown
The New England Journal of Medicine|October 15, 2025
More about the Phase 2a Study of Baxdrostat in Primary Aldosteronism. ReplyAdina F Turcu, Mason W Freeman, Morris J Brown
Annals of Medicine|July 20, 2005
Atherosclerosis and innate immune signalingMarc A Laberge, Kathryn J Moore, Mason W Freeman
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 2, 2006
Statins, cholesterol, and the prevention of coronary heart diseaseMason W Freeman
Arteriosclerosis, Thrombosis, and Vascular Biology|May 27, 2006
Scavenger receptors in atherosclerosis: beyond lipid uptakeKathryn J Moore, Mason W Freeman
Drug Discovery Today. Therapeutic Strategies|May 12, 2009
Targeting Innate Immunity for CV BenefitKathryn J Moore, Mason W Freeman
Nature Medicine|February 4, 2003
eLiXiRs for restraining inflammationMason W Freeman, Kathryn J Moore
The New England Journal of Medicine|October 24, 2019
Case 22-2019: A 65-Year-Old Woman with Myopathy. ReplyMason W Freeman, Amanda C Guidon, Sheila L Arvikar
Biochemical and Biophysical Research Communications|October 3, 2003
Activation of signaling pathways by putative scavenger receptor class A (SR-A) ligands requires CD14 but not SR-AWoojin Scott Kim, Christine M Ordija, Mason W Freeman
Journal of Molecular Medicine (Berlin, Germany)|May 22, 2002
Nuclear hormone receptors and cholesterol trafficking: the orphans find a new homeMichael L Fitzgerald, Kathryn J Moore, Mason W Freeman
The New England Journal of Medicine|May 10, 2023
Baxdrostat for Treatment-Resistant Hypertension. ReplyMason W Freeman, Yuan-Di Halvorsen, Morris J Brown
The New England Journal of Medicine|October 15, 2025
More about the Phase 2a Study of Baxdrostat in Primary Aldosteronism. ReplyAdina F Turcu, Mason W Freeman, Morris J Brown
Annals of Medicine|July 20, 2005
Atherosclerosis and innate immune signalingMarc A Laberge, Kathryn J Moore, Mason W Freeman
Pageof 7